8-K: PetVivo Holdings Secures $5 Million Equity Financing Amidst Nasdaq Delisting Concerns

PetVivo Holdings, Inc. announces a $5 million equity financing agreement through the sale of Series B Convertible Preferred Stock, while still navigating the delisting process from Nasdaq.

Summary

• PetVivo Holdings, Inc. has entered into a Subscription Agreement to receive $5 million in equity financing.
• The financing involves the issuance of 5 million shares of Series B Convertible Preferred Stock.
• The company received an initial $600,000 on March 26, 2025.
• The investor has an option to invest an additional $4.4 million within the next 60 days under the same terms.
• The offering is exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
• The Series B Preferred Stock will have restricted securities status under Rule 144 of the Securities Act.
• Each holder of Series B Convertible Preferred Stock shall have that number of votes on all matters submitted to the shareholders that is equal to the number of shares of Common Stock into which such holders shares of Series B Convertible Preferred Stock are then convertible.
• The Series B Preferred Stock is entitled to receive a specific dividend in an annual amount equal to Ten Percent (10%) of the total amount paid to secure the Series B Convertible Preferred Stock.
• The dividend shall be paid to the holder by the Company in quarterly payments of Company Common Stock.
• Following the second year anniversary of the issuance of the Series B Convertible Preferred Stock, the Company shall have the right, at its discretion, to call for the purchase of all or a portion of the shares of Series B Convertible Preferred Stock (Call Option) by providing the Holder written notice of the intent to exercise the Call Option on the thirtieth (30th) day from the receipt of notice by the Holder.
• The call price for each share of Series B Convertible Preferred Stock the Company desires to purchase pursuant to the Call Option shall be at a price of One Dollar and Fifteen Cents ($1.15) per share.
• The company's securities were suspended from trading on The Nasdaq Stock Market (Nasdaq) on April 5, 2024.
• On June 24, 2024, the Company received a decision from the Nasdaq Listing Council affirming the decision by the Nasdaq Hearing Panel to delist the Companys securities from Nasdaq.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While securing financing is positive, the potential Nasdaq delisting and the terms of the preferred stock offering raise concerns.

Positives

• The company successfully secured $5 million in equity financing, providing capital for operations and growth.
• The investor has the option to invest an additional $4.4 million, potentially increasing the total financing to $9.4 million.
• The Series B Preferred Stock includes a 10% annual dividend, providing a return to investors.
• The company retains the option to repurchase the shares after two years, offering potential flexibility.

Negatives

• The company's securities were suspended from trading on The Nasdaq Stock Market (Nasdaq) on April 5, 2024.
• The company is facing potential delisting from Nasdaq, which could negatively impact stock liquidity and investor confidence.
• The offering involves the issuance of preferred stock, which could dilute the value of existing common stock.
• The company's management has broad discretion in the application of the net proceeds, and the Subscriber will be relying on the judgment of our management regarding the application of the net proceeds of this offering.

Risks

• The company faces the risk of Nasdaq delisting, which could reduce stock liquidity and accessibility for investors.
• The additional $4.4 million investment is not guaranteed, as it is subject to the investor's option.
• The company's management has broad discretion in the application of the net proceeds, and the Subscriber will be relying on the judgment of our management regarding the application of the net proceeds of this offering.
• The company's securities are speculative and involve a high degree of risk and immediate substantial dilution, and they should not be purchased by any investor who cannot afford the loss of this entire investment.

Future Outlook

The company anticipates receiving the remaining $4.4 million of the Offering proceeds within the next sixty days of execution of the Subscription Agreement. PetVivo intends to use the net proceeds from this offering primarily for commercialization of its lead products Spryng with OsteoCushion Technology and PrecisePRP, to finance clinical trials and to fund working capital and general corporate purposes.

Management Comments

• The offering price of the Shares has been determined arbitrarily by the management of PetVivo, and bears no particular relationship to our net worth, revenues or any other standard criteria of value.
• Our management will have broad discretion in the application of the net proceeds, and the Subscriber will be relying on the judgment of our management regarding the application of the net proceeds of this offering.

Industry Context

The financing comes at a challenging time for PetVivo, as it faces potential delisting from Nasdaq. Securing this funding could provide the company with the resources needed to address its listing issues and continue its business operations. The animal health industry is competitive, and access to capital is crucial for companies to develop and commercialize their products.

Comparison to Industry Standards

• It is difficult to compare PetVivo's financing to industry standards without knowing the specific terms of the Series B Convertible Preferred Stock, such as conversion ratios and liquidation preferences.
• Similar companies in the animal health sector, such as Zoetis or Elanco, typically have access to more traditional forms of financing due to their established market positions.
• Smaller, development-stage companies often rely on venture capital or private equity, which may come with more stringent terms than traditional debt financing.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new preferred stock.
• Employees may benefit from the increased financial stability provided by the financing.
• Customers may see improved product availability and development as a result of the funding.
• The company's ability to meet its obligations to suppliers and creditors may be strengthened by the financing.

Next Steps

• The company anticipates receiving the remaining $4.4 million from the investor within 60 days.
• PetVivo will likely focus on utilizing the funds to commercialize its products and fund clinical trials.
• The company will need to address the Nasdaq delisting issue to maintain its listing status.

Key Dates

Keywords

equity financing, Series B Convertible Preferred Stock, subscription agreement, PetVivo Holdings, Nasdaq delisting, capital raise